Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 8, Issue 3, Pages 292-299Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2008.04.006
Keywords
-
Categories
Funding
- NHLBI NIH HHS [P50 HL060280, P50 HL060280-060001, P01 HL034322-220013, P01 HL034322-14, P01 HL034322, P50 HL060280-010001, P01 HL034322-120005] Funding Source: Medline
Ask authors/readers for more resources
Although cystic fibrosis (CF) patients display multiorgan dysfunction (e.g. pancreas, gut, and lung) it is lung disease that is the leading cause of premature death in these patients. CIF lung disease is characterized by persistent pulmonary infection and mucus plugging of the airways initiated by the failure of solute transport across the airway epithelium. Many drug therapies aim to alleviate the secondary characteristics of CF lung disease; however, new therapies in development are targeted at correcting the ion transport deficiency of CF. The goal is to hydrate airway surfaces by stimulating secretion (through activation of the CF transmembrane conductance regulator and calcium-activated chloride channels), and/or inhibiting absorption (through the epithelial sodium channel) thereby stimulating healthy mucociliary clearance. If mucociliary clearance can be stimulated sufficiently from an early age, then there is the possibility that secondary lung infection may be eradicated from the syndrome of CF disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available